Loading…

Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy a thermosensitive liposome system to stimulate tumor-specific immunological response

Immune checkpoint blockade (ICB) therapy in combination with immunogenic death (ICD) triggered by photothermal therapy (PTT) and oxaliplatin (OXA) treatment was expected to elicit both innate and adaptive immune responses for tumor control and metastasis prevention. In this study, a photothermal age...

Full description

Saved in:
Bibliographic Details
Published in:Nanoscale 2021-08, Vol.13 (3), p.12966-12978
Main Authors: Yu, Jie, He, Xidong, Wang, Zigui, Wang, Yupeng, Liu, Sha, Li, Xiaoyuan, Huang, Yubin
Format: Article
Language:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint blockade (ICB) therapy in combination with immunogenic death (ICD) triggered by photothermal therapy (PTT) and oxaliplatin (OXA) treatment was expected to elicit both innate and adaptive immune responses for tumor control and metastasis prevention. In this study, a photothermal agent (IR780), a folic acid (FA) linked oxaliplatin (OXA) prodrug, and PD-L1 inhibitors (BMS-1) were integrated into a liposomal system. The FA tumor-targeting and enhanced permeability and retention (EPR) effect of the liposomal system prolonged circulating times and increased accumulation in tumors, resulting in an enhanced photothermal effect and less systemic toxicity. In addition, PTT and OXA had a considerable synergistic effect in the induction of a combined ICD. The PD-1/PD-L1 checkpoint, which is a negative immune regulatory mechanism, could be blocked by the thermosensitive released BMS-1. Finally, ICD was harnessed to synergize with a small molecule PD-L1 inhibitor for activation of the immune system in the treatment of tumor relapse and metastasis. The combination of ICB and ICD induced by PTT and OXA significantly promoted antigen presentation and infiltration of CTLs, which inhibited the relapse, regeneration, and metastasis of tumor cells.
ISSN:2040-3364
2040-3372
DOI:10.1039/d1nr03288g